NCT07457528 2026-03-11
Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
Clinical Trials
12 trialsNCT06770452 2025-09-23
HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients
Zhejiang University
Phase 2 Recruiting
NCT06509009 2025-09-19
Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT07070479 2025-09-18
Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
Sun Yat-sen University
Phase 2 Recruiting
NCT06988956 2025-05-25
Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT06912711 2025-05-21
TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2 Recruiting
NCT06722911 2024-12-09
Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer
Zhejiang Provincial People's Hospital
Phase 2 Recruiting
NCT06389760 2024-10-31
Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Recruiting
NCT06429839 2024-05-28
Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06413017 2024-05-14
Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT06410651 2024-05-13
Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06259721 2024-03-07
Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma
Jiangxi Provincial Cancer Hospital
Phase 2 Recruiting